Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 1/2016

01-02-2016

Off-Label Uses of Omalizumab

Author: David El-Qutob

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2016

Login to get access

Abstract

The off-label use of medicines is a common and extensive clinical practice. Omalizumab has been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing was based on body weight and baseline serum IgE concentration. All patients are required to have a baseline IgE between 30 and 700 IU/ml and body weight not more than 150 kg. The use of off-label drugs may lead to several problems including adverse effects and an increased risk/benefit balance. In this article, there are summarized off-label uses of omalizumab in the last recent years in diseases in which IgE maybe or certainly has a corner role such as allergic rhinitis, allergic bronchopulmonary aspergillosis, anaphylaxis, keratoconjunctivitis, food allergy, drug allergy, urticaria, angioedema, non-atopic asthma, atopic dermatitis, nasal polyps, Churg-Strauss syndrome, eosinophilic otitis media, chronic rhinosinusitis, bullous pemphigoid, contact dermatitis, and others. Use in pregnancy asthmatic women and pre-co-administration with specific immunotherapy will also be revised.
Literature
1.
Blondon K, Desmeules J, Vogt-Ferrier N, Besson M, Kondo-Oestreicher M, Dayer P (2008) Off-label prescribing. Rev Med Suisse 4(165):1661–5, La prescription “off-label”PubMed
2.
Radley DC, Finkelstein SN, Stafford RS (2006) Off-label prescribing among office-based physicians. Arch Intern Med 166(9):1021–6PubMedCrossRef
3.
Kesselheim AS, Mello MM, Avorn J (2013) FDA regulation of off-label drug promotion under attack. JAMA 309(5):445–6PubMedCrossRef
4.
Baird B, Shopes RJ, Oi VT, Erickson J, Kane P, Holowka D (1989) Interaction of IgE with its high-affinity receptor structural basis and requirements for effective cross-linking. Int Arch Allergy Appl Immunol 88(1–2):23–8PubMedCrossRef
5.
Makris MP, Papadavid E, Zuberbier T (2014) The use of biologicals in cutaneous allergies—present and future. Curr Opin Allergy Clin Immunol 14(5):409–16PubMedCrossRef
6.
Khan S, Deacock S (2011) Expanding indications of omalizumab therapy in the absence of specific IgE. Allerg Immunol (Madr) 39(3):189CrossRef
7.
8.
Babu KS, Polosa R, Morjaria JB (2013) Anti-IgE–emerging opportunities for omalizumab. Expert Opin Biol Ther 13(5):765–77PubMedCrossRef
9.
Danes I, Agusti A, Vallano A, Alerany C, Martinez J, Bosch JA et al (2014) Outcomes of off-label drug uses in hospitals: a multicentric prospective study. Eur J Clin Pharmacol 70(11):1385–93PubMedCentralPubMedCrossRef
10.
Hirashima J, Hojo M, Iikura M, Hiraishi Y, Nakamichi S, Sugiyama H et al (2012) A case of an asthma patient receiving omalizumab during pregnancy. Arerugi 61(11):1683–7PubMed
11.
Kuprys-Lipinska I, Tworek D, Kuna P (2014) Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies. Postepy dermatologii i alergologii 31(2):104–7PubMedCentralPubMed
12.
Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Jr., Chen H, Carrigan G, et al. (2014) The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. J Allergy Clin Immunol
13.
Johansson SG, Oman H, Nopp A, Pettersson S (2006) The importance of IgE antibody levels in anti-IgE treatment. Allergy 61(10):1216–9PubMedCrossRef
14.
Ankerst J, Nopp A, Johansson SG, Adedoyin J, Oman H (2010) Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 152(1):71–4PubMedCrossRef
15.
Maselli DJ, Singh H, Diaz J, Peters JI (2013) Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study. Ann Allergy Asthma Immunol 110(6):457–61PubMedCrossRef
16.
Vennera Mdel C, Picado C (2014) Novel diagnostic approaches and biological therapeutics for intrinsic asthma. Int J General Med 7:365–71CrossRef
17.
de Llano LP, Vennera Mdel C, Alvarez FJ, Medina JF, Borderias L, Pellicer C et al (2013) Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma 50(3):296–301PubMedCrossRef
18.
Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C et al (2013) A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 144(2):411–9PubMedCrossRef
19.
Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM (2013) Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents 27(1):45–53PubMed
20.
Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA et al (2003) Allergic bronchopulmonary Aspergillosis in cystic fibrosis–state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis 37(Suppl 3):S225–64PubMedCrossRef
21.
Knutsen AP, Slavin RG. (2011) Allergic Bronchopulmonary Aspergillosis in Asthma and Cystic Fibrosis. Clinical and Developmental Immunology
22.
Greenberger PA, Patterson R (1988) Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol 81(4):646–50PubMedCrossRef
23.
Laufer P, Fink JN, Bruns WT, Unger GF, Kalbfleisch JH, Greenberger PA et al (1984) Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol 73(1 Pt 1):44–8PubMedCrossRef
24.
Zicari AM, Celani C, De Castro G, Valerio De Biase R, Duse M (2014) Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis. Eur Rev Med Pharmacol Sci 18(13):1839–41PubMed
25.
Tanou K, Zintzaras E, Kaditis AG (2014) Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 49(5):503–7PubMedCrossRef
26.
van der Ent CK, Hoekstra H, Rijkers GT (2007) Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62(3):276–7PubMedCentralPubMedCrossRef
27.
Lehmann S, Pfannenstiel C, Friedrichs F, Kroger K, Wagner N, Tenbrock K (2014) Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ther Adv Respir Dis 8(5):141–9PubMedCrossRef
28.
Jat KR, Walia DK, Khairwa A (2013) Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 9:CD010288PubMed
29.
Tillie-Leblond I, Germaud P, Leroyer C, Tetu L, Girard F, Devouassoux G et al (2011) Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 66(9):1254–6PubMedCrossRef
30.
Perez-de-Llano LA, Vennera MC, Parra A, Guallar J, Marin M, Asensio O et al (2011) Effects of omalizumab in aspergillus-associated airway disease. Thorax 66(6):539–40PubMedCrossRef
31.
Sastre I, Blanco J, Mata H, Garcia F (2012) A case of allergic bronchopulmonary aspergillosis treated with omalizumab. J Investig Allergol Clin Immunol 22(2):145–7PubMed
32.
Collins J, Devos G, Hudes G, Rosenstreich D (2012) Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma and Allergy 5:65–70CrossRef
33.
Homma T, Kurokawa M, Matsukura S, Yamaguchi M, Adachi M. (2013) Anti-IgE therapy for allergic bronchopulmonary aspergillosis. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
34.
Gonzalez de Olano D, Gonzalez-Mancebo E, Gandolfo Cano M, Melendez Baltanas A, Valeri-Busto V, Maracionero MA et al (2009) Successful treatment of allergic bronchopulmonary candidiasis with a recombinant anti-immunoglobulin E antibody. J Investig Allergol Clin Immunol 19(5):416–7PubMed
35.
Wolf BL, Johnson A (2014) Unexpected decrease in total IgE in a patient with allergic bronchopulmonary aspergillosis treated with omalizumab. J Allergy Clin Immunol Prac 2(1):111–3CrossRef
36.
El-Qutob LD (2012) New methods of prevention and treatment of allergic diseases. Recent Patents Inflamm Allergy Drug Discov 6(1):46–64CrossRef
37.
Ridolo E, Montagni M, Melli V, Braido F, Incorvaia C, Canonica GW (2014) Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother 15(1):73–83PubMedCrossRef
38.
Vashisht P, Casale T (2013) Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther 13(6):933–45PubMedCrossRef
39.
40.
Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109(2):274–80PubMedCrossRef
41.
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al (2009) Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 39(2):271–9PubMedCrossRef
42.
Okubo K, Nagakura T (2008) Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update. Allergol Int 57(3):205–9PubMedCrossRef
43.
Ogino S, Nagakura T, Okubo K, Sato N, Takahashi M, Ishikawa T (2009) Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 149(3):239–45PubMedCrossRef
44.
Penn R, Mikula S (2007) The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 21(4):428–32PubMedCrossRef
45.
Guglielmo M, Gulotta C, Mancini F, Sacchi M, Tarantini F (2009) Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab. J Investig Allergol Clin Immunol 19(2):158–9PubMed
46.
Grundmann SA, Hemfort PB, Luger TA, Brehler R (2008) Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol 121(1):257–8PubMedCrossRef
47.
Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M (2011) Efficacy of omalizumab in the treatment of nasal polyps. Thorax 66(9):824–5PubMedCrossRef
48.
Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K et al (2013) Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol 110(5):387–8PubMedCrossRef
49.
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110–6PubMedCrossRef
50.
Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318–24PubMed
51.
Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al (1990) The American college of rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094–100PubMedCrossRef
52.
Ruppert AM, Averous G, Stanciu D, Deroide N, Riehm S, Poindron V et al (2008) Development of churg-strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 121(1):253–4PubMedCrossRef
53.
Churg A, Brallas M, Cronin SR, Churg J (1995) Formes frustes of churg-strauss syndrome. Chest 108(2):320–3PubMedCrossRef
54.
55.
Bargagli E, Madioni C, Olivieri C, Penza F, Rottoli P (2008) Churg-strauss vasculitis in a patient treated with omalizumab. J Asthma 45(2):115–6PubMedCrossRef
56.
Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L (2009) Churg-strauss syndrome in patients treated with omalizumab. Chest 136(2):507–18PubMedCrossRef
57.
Graziani A, Quercia O, Girelli F, Martelli A, Mirici Cappa F, Stefanini GF (2014) Omalizumab treatment in patient with severe asthma and eosinophilic granulomatosis with polyangiitis a case report. Eur Ann Allergy Clin Immunol 46(6):226–8PubMed
58.
Pabst S, Tiyerili V, Grohe C (2008) Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg-Strauss syndrome. Thorax 63(8):747–8PubMedCrossRef
59.
Iglesias E, Camacho Lovillo M, Delgado Pecellin I, Lirola Cruz MJ, Falcon Neyra MD, Salazar Quero JC et al (2014) Successful management of churg-strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case. Pediatr Pulmonol 49(3):E78–81PubMedCrossRef
60.
Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J (2007) Administration of anti-IgE to a churg-strauss syndrome patient. Int Arch Allergy Immunol 144(2):155–8PubMedCrossRef
61.
Spina MF, Miadonna A (2009) Role of omalizumab and steroids in churg-strauss syndrome. J Allergy Clin Immunol 124(3):600–1PubMedCrossRef
62.
Kaya H, Gumus S, Ucar E, Aydogan M, Musabak U, Tozkoparan E et al (2012) Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest 142(2):513–6PubMedCrossRef
63.
Domingo C, Pomares X (2013) Can omalizumab be effective in chronic eosinophilic pneumonia? Chest 143(1):274PubMedCrossRef
64.
Barnig C, Hilger C, Muti D, Blaumeiser M, Purohit A, Hentges F et al (2012) Anaphylaxis to vapors of roasting chicken controlled by omalizumab. J Investig Allergol Clin Immunol 22(6):439–40PubMed
65.
Perez Pimiento A, Bueso Fernandez A, Garcia Loria J, Rodriguez Cabreros MI, Mosquera MR, Garcia CA (2008) Effect of omalizumab treatment in a baker with occupational asthma. J Investig Allergol Clin Immunol 18(6):490–1PubMed
66.
Olivieri M, Biscardo CA, Turri S, Perbellini L (2008) Omalizumab in persistent severe bakers’ asthma. Allergy 63(6):790–1PubMedCrossRef
67.
Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R et al (2013) Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy 68(6):813–5PubMedCrossRef
68.
Brown R, Turk F, Dale P, Bousquet J (2007) Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62(2):149–53PubMedCrossRef
69.
70.
Baker R. (1998) FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation. 8–9
71.
O’Reilly J, Dalal A (2003) Off-label or out of bounds? prescriber and marketer liability for unapproved uses of FDA-approved drugs. Annals Health Law / Loyola Univ Chicago, School Law Ins Health Law 12(2):295–324, table of contents
72.
Turner S, Gill A, Nunn T, Hewitt B, Choonara I (1996) Use of “off-label” and unlicensed drugs in paediatric intensive care unit. Lancet 347(9000):549–50PubMedCrossRef
73.
Krathen RA, Hsu S (2005) Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53(2):338–40PubMedCrossRef
74.
Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54(1):68–72PubMedCrossRef
75.
Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55(1):168–70PubMedCrossRef
76.
Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al (2007) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120(5):1223–5PubMedCrossRef
77.
Forman SB, Garrett AB (2007) Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor. FcepsilonRI Cutis 80(1):38–40PubMed
78.
Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG (2008) Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 69(2):78–80PubMed
79.
Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29(5):530–7PubMedCrossRef
80.
Caruso C, Gaeta F, Valluzzi RL, Romano A (2010) Omalizumab efficacy in a girl with atopic eczema. Allergy 65(2):278–9PubMedCrossRef
81.
82.
Thaiwat S, Sangasapaviliya A (2011) Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol 29(4):357–60PubMed
83.
Ramirez del Pozo ME, Contreras Contreras E, Lopez Tiro J, Gomez VJ (2011) Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol 21(5):416–7PubMed
84.
Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, Paravisini A, Sanchez-Ramon S, Suarez FR (2012) Omalizumab for the treatment of atopic dermatitis. Actas Dermo-sifilio Graficas 103(7):624–8CrossRef
85.
Sanchez-Ramon S, Eguiluz-Gracia I, Rodriguez-Mazariego ME, Paravisini A, Zubeldia-Ortuno JM, Gil-Herrera J et al (2013) Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 23(3):190–6PubMed
86.
Kim DH, Park KY, Kim BJ, Kim MN, Mun SK (2013) Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 38(5):496–500PubMedCrossRef
87.
Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT et al (2013) Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162(1):89–93PubMedCentralPubMedCrossRef
88.
Toledo F, Silvestre JF, Munoz C (2012) Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis report of four cases. J Eur Acad Dermatol Venereol 26(10):1325–7PubMedCrossRef
89.
Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe N, Ollert M, Folster-Holst R et al (2014) Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 69(1):132–5PubMedCrossRef
90.
Fairman KA, Curtiss FR (2010) Regulatory actions on the off-label use of prescription drugs: ongoing controversy and contradiction in 2009 and 2010. J Manag Care Pharm JMCP 16(8):629–39PubMed
91.
Messingham KA, Holahan HM, Fairley JA (2014) Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid. Immunol Res 59(1–3):273–8PubMedCrossRef
92.
Fairley JA, Baum CL, Brandt DS, Messingham KA (2009) Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 123(3):704–5PubMedCrossRef
93.
London VA, Kim GH, Fairley JA, Woodley DT (2012) Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol 148(11):1241–3PubMedCrossRef
94.
Dufour C, Souillet AL, Chaneliere C, Jouen F, Bodemer C, Jullien D et al (2012) Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol 166(5):1140–2PubMedCrossRef
95.
Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT (2014) Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 71(3):468–74PubMedCrossRef
96.
Yalcin AD, Genc GE, Celik B, Gumuslu S (2014) Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab 60(3):523–4PubMed
97.
Nonaka M, Sakitani E, Yoshihara T (2014) Anti-IgE therapy to Kimura’s disease: a pilot study. Auris Nasus Larynx 41(4):384–8PubMedCrossRef
98.
Centers for medicare & medicaid services: off-label use of colorectal cancer drugs allowed in select clinical trials. Journal of oncology practice / American Society of Clinical Oncology. (2005)1(1):12–4
99.
Chularojanamontri L, Wimoolchart S, Tuchinda P, Kulthanan K, Kiewjoy N (2009) Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol 27(4):233–6PubMed
100.
Rodriguez-Rodriguez M, Antolin-Amerigo D, Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Alvarez-Mon M (2014) Successful treatment of severe delayed pressure angio-oedema with omalizumab. Allergol Immun (Madr) 42(1):78–80CrossRef
101.
Bindslev-Jensen C, Skov PS (2010) Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 65(1):138–9PubMedCrossRef
102.
Ozturk AB, Kocaturk E, Ozturk E (2014) Successful treatment of a bullous urticaria with omalizumab. Allergol Int 63(3):495–7PubMedCrossRef
103.
Pressler A, Grosber M, Halle M, Ring J, Brockow K (2013) Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clin Exp Dermatol 38(2):151–3PubMedCrossRef
104.
Mur Gimeno P, Martin Iglesias A, Lombardero Vega M, Bautista Martinez P, Ventura LP (2013) Occupational wheat contact dermatitis and treatment with omalizumab. J Investig Allergol Clin Immunol 23(4):287–8PubMed
105.
Carballada F, Nunez R, Martin-Lazaro J, Juarez Y, Castineira I, Fernandez L et al (2013) Omalizumab treatment in 2 cases of refractory heat urticaria. J Investig Allergol Clin Immunol 23(7):519–21PubMed
106.
Bullerkotte U, Wieczorek D, Kapp A, Wedi B (2010) Effective treatment of refractory severe heat urticaria with omalizumab. Allergy 65(7):931–2PubMedCrossRef
107.
Duchini G, Baumler W, Bircher AJ, Scherer K (2011) Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 27(6):336–7PubMedCrossRef
108.
Guzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M (2008) Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 63(11):1563–5PubMedCrossRef
109.
Sands MF, Blume JW, Schwartz SA (2007) Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 120(4):979–81PubMedCrossRef
110.
Larenas-Linnemann D, Wahn U, Kopp M (2014) Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 133(3):937–e2PubMedCrossRef
111.
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117(1):134–40PubMedCrossRef
112.
Stelmach I, Sztafinska A, Woicka-Kolejwa K, Jerzynska J (2014) Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report. Postepy dermatologii i alergologii 31(3):191–3PubMedCentralPubMed
113.
Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP et al (2010) Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125(2):383–9PubMedCrossRef
114.
Tartibi HM, Majmundar AR, Khan DA (2010) Successful use of omalizumab for prevention of fire ant anaphylaxis. J Allergy Clin Immunol 126(3):664–5PubMedCrossRef
115.
Tille KS, Parker AL (2014) Imported fire ant rush desensitization using omalizumab and a premedication regimen. Ann Allergy Asthma Immunol 113(5):574–6PubMedCrossRef
116.
Wieczorek D, Kapp A, Wedi B (2014) Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab. Hautarzt 65(9):791–5, Unvertraglichkeit der spezifischen Immuntherapie mit Hymenopterengift: Mit Omalizumab die Hurde nehmenPubMedCrossRef
117.
Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH et al (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348(11):986–93PubMedCrossRef
118.
Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM et al (2011) A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127(5):1309–10PubMedCrossRef
119.
Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT (2013) A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 132(6):1368–74PubMedCentralPubMedCrossRef
120.
Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA (2012) Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 130(5):1123–9PubMedCentralPubMedCrossRef
121.
Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT (2011) Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 127(6):1622–4PubMedCentralPubMedCrossRef
122.
Begin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B et al (2014) Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 10(1):7PubMedCentralPubMedCrossRef
123.
Lafuente I, Mazon A, Nieto M, Uixera S, Pina R, Nieto A. (2014) Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg. Pediatr Allergy Immunol
124.
125.
Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J et al (2011) Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 170(11):1471–4PubMedCrossRef
126.
127.
Kontou-Fili K (2008) High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63(3):376–8PubMedCrossRef
128.
Sokol KC, Ghazi A, Kelly BC, Grant JA (2014) Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Prac 2(3):266–70CrossRef
129.
da Silva EN, Randall KL (2013) Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin Immunol Prac 1(6):687–8CrossRef
130.
Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O’Hehir RE (2010) Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 65(7):926–7PubMedCrossRef
131.
Jagdis A, Vadas P (2014) Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol 113(1):115–6PubMedCrossRef
132.
Paraskevopoulos G, Sifnaios E, Christodoulopoulos K, Mantopoulou F, Papakonstantis M, Sabaziotis D (2013) Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy. Eur Ann Allergy Clin Immunol 45(2):52–5PubMed
133.
Matito A, Blazquez-Goni C, Morgado JM, Alvarez-Twose I, Mollejo M, Sanchez-Munoz L et al (2013) Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol 111(5):425–6PubMedCrossRef
134.
Bell MC, Jackson DJ (2012) Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 108(5):383–4PubMedCentralPubMedCrossRef
135.
Kibsgaard L, Skjold T, Deleuran M, Vestergaard C (2014) Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. Acta Derm Venereol 94(3):363–4PubMedCrossRef
136.
Siebenhaar F, Kuhn W, Zuberbier T, Maurer M (2007) Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 120(1):213–5PubMedCrossRef
137.
Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD (2007) Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 119(6):1550–1PubMedCrossRef
138.
Bray SM, Fajt ML, Petrov AA (2012) Successful treatment of exercise-induced anaphylaxis with omalizumab. Ann Allergy Asthma Immunol 109(4):281–2PubMedCrossRef
139.
140.
Demirturk M, Gelincik A, Colakoglu B, Dal M, Buyukozturk S (2012) Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol 39(6):552–4PubMedCrossRef
141.
Jones JD, Marney SR Jr, Fahrenholz JM (2008) Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 101(5):550–1PubMedCrossRef
142.
Berges-Gimeno MP, Simon RA, Stevenson DD (2003) Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111(1):180–6PubMedCrossRef
143.
Bobolea I, Barranco P, Fiandor A, Cabanas R, Quirce S (2010) Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 20(5):448–9PubMed
144.
Aksu K, Kurt E (2013) Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol Immunopathol (Madr) 41(3):208–10CrossRef
145.
Vogel Z, Towbin M, Daniels MP (1979) Alpha-bungarotoxin-horseradish peroxidase conjugate: preparation, properties and utilization for the histochemical detection of acetylcholine receptors. J Histochem Cytochem 27(4):846–51PubMedCrossRef
146.
Matheu V, Franco A, Perez E, Hernandez M, Barrios Y (2007) Omalizumab for drug allergy. J Allergy Clin Immunol 120(6):1471–2, author reply 2–3 PubMedCrossRef
147.
Cavelti-Weder C, Muggli B, Keller C, Babians-Brunner A, Biason-Lauber A, Donath MY et al (2012) Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care 35(6):e41PubMedCentralPubMedCrossRef
148.
Yong PF, Malik R, Arif S, Peakman M, Amiel S, Ibrahim MA et al (2009) Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med 360(10):1045–7PubMedCrossRef
149.
Ojaimi S, Harnett PR, Fulcher DA (2014) Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. J Allergy Clin Immunol Prac 2(1):105–6CrossRef
150.
Heinz C, Heiligenhaus A (2014) Vernal keratoconjunctivitis. Klin Monbl Augenheilkd 231(5):505–11, Keratoconjunctivitis vernalisPubMedCrossRef
151.
Vichyanond P, Pacharn P, Pleyer U, Leonardi A (2014) Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol 25(4):314–22PubMedCrossRef
152.
Sanchez J, Omalizumab CR (2012) An option in vernal keratoconjunctivitis? Allergol Immunopathol (Madr) 40(5):319–20CrossRef
153.
de Klerk TA, Sharma V, Arkwright PD, Biswas S (2013) Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS Off Pub Am Assoc Ped Ophthalmol Strabismus Am Assoc Ped Ophthalmol Strabismus 17(3):305–6CrossRef
154.
Matsutani S, Kobayashi T, Kousaka T (1995) Eosinophilic otitis media. Otolaryngol Head Neck Surg 67(8):712–3
155.
Kawano T, Ishitoya J, Tsukuda M (2007) Sinusitis with eosinophilic otitis media. Practica Oto-Rhino-Laryngologica 100(9):715–24CrossRef
156.
Okude A, Tagaya E, Kondo M, Nonaka M, Tamaoki J (2012) A case of severe asthma with eosinophilic otitis media successfully treated with anti-IgE monoclonal antibody omalizumab. Case Rep Pulmonol 2012:340525PubMedCentralPubMed
157.
Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H et al (2012) Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. Otology Neurotol Off Publ Am Otolog Soc Am Neurotol Soc [and] Eur Acad Otolog Neurotol 33(7):1218–24CrossRef
158.
Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H et al (2014) Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media. Acta Otolaryngol 134(4):366–72PubMedCrossRef
Metadata
Title
Off-Label Uses of Omalizumab
Author
David El-Qutob
Publication date
01-02-2016
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2016
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-015-8490-y

Other articles of this Issue 1/2016

Clinical Reviews in Allergy & Immunology 1/2016 Go to the issue

ReviewPaper

Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response

OriginalPaper

Hereditary Angioedema Attacks: Local Swelling at Multiple Sites

ReviewPaper

Histamine (Scombroid) Fish Poisoning: a Comprehensive Review

ReviewPaper

CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases

OriginalPaper

The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis

ReviewPaper

Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits